1. An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study. (2019) Authors: Molloy, K.; Jonak, C.; Sherida, F.J.; Woei-A-Ji, H.; Guenova, E.; Busschots, A.M.; Bervoets, A.; Hauben, E.; Knobler, R.; Porkert, S.; Fassnacht, C.; Cowan, R.; Papadavid, E.; Beylot-Barry, M.; Berti, E.; Alberti Violetti, S.; Estrach, T.; Matin, R.; Akilov, O.; Vakeva, L. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Morschhauser, F.; Tilly, H.; Chaidos, A.; Phillips, T.; Ribrag, V.; Campbell, P.; Ghandi Laurent, D.; Jurczak, W.; McKay, P.; Opat, S.; Radford, J.; Rajarethinam, A.; Yang, J.; Howell, H.; Newberry, K.J.; Adib, D.; Salles, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TOLERABILITY OF HIGH DOSE INTRAVENOUS METHOTREXATE FOR CNS PROPHYLAXIS INTERCALATED WITH R‐CHOP – A SINGLE CENTRE RETROSPECTIVE ANALYSIS. (12th June 2019) Authors: Wilson, M.R.; Feather, C.; Leach, M.; McKay, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019) Authors: Davies, A.J.; Tansley Hancock, O.; Cummin, T.; Caddy, J.; Stanton, L.; Burton, C.; Barrans, S.; Coleman, A.; Osborne, W.; McKay, P.; Griffiths, G.; Johnson, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE / PROCARBAZINE SUBSTITUTION REDUCES RED CELL TRANSFUSION REQUIREMENTS AND MAY SHORTEN TIME TO MENSTRUAL PERIOD RECOVERY. (12th June 2019) Authors: Follows, G.; Santarsieri, A.; Sturgess, K.; Menne, T.; Osborne, W.; Creasey, T.; Ardeshna, K.M.; Behan, S.; Booth, S.; Collins, G.; Cwynarski, K.; Iyengar, S.; Jones, S.; Martinez‐Calle, N.; McKay, P.; Nagumantry, S.K.; O'Mahony, D.; Rudge, J.F.; Shah, N.; Stafford, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. (June 2017) Authors: Blakemore, S.J.; Daigle, S.R.; McDonald, A.A.; Morschhauser, F.; Ribrag, V.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Le Gouill, S.; Fruchart, C.; Radford, J.; Zinzani, P.L.; Assouline, S.; Cartron, G.; Dickinson, M.; Morin, R.; Wu, H.; Sausen, M.; Clawson, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS. (June 2017) Authors: Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M.J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P.L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. CHOP VERSUS GEM‐P IN THE FIRST‐LINE TREATMENT OF T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO‐T TRIAL. (June 2017) Authors: Gleeson, M.; Peckitt, C.; To, Y.M.; Edwards, L.; Chau, I.; Johnson, P.; Ardeshna, K.M.; Wotherspoon, A.; Attygalle, A.; Begum, R.; Chua, S.; Zerizer, I.; Hawkes, E.A.; Macheta, M.P.; Collins, G.P.; Radford, J.A.; Forbes, A.; Hart, A.; Montoto, S.; McKay, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THE ROLE OF 18F FDG‐PET/CT IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO‐T TRIAL PET/CT SUBSTUDY. (June 2017) Authors: Gleeson, M.; Peckitt, C.; Cunningham, D.; To, Y.M.; Edwards, L.; Chau, I.; Johnson, P.; Ardeshna, K.M.; Wotherspoon, A.; Attygalle, A.; Begum, R.; Zerizer, I.; Hawkes, E.A.; Macheta, M.P.; Collins, G.P.; Radford, J.A.; Forbes, A.; Hart, A.; Montoto, S.; McKay, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A study of quality of life in people with mycosis fungoides and Sézary syndrome. (28th February 2020) Authors: Molloy, K.; Jonak, C.; Sherida, F.J.; Woei‐A‐Ji, H.; Guenova, E.; Busschots, A.M.; Bervoets, A.; Hauben, E.; Knobler, R.; Porkert, S.; Fassnacht, C.; Cowan, R.; Papadavid, E.; Beylot‐Barry, M.; Berti, E.; Alberti Violetti, S.; Estrach, T.; Matin, R.; Akilov, O.; Vakeva, L. Journal: British journal of dermatology Issue: Volume 182:Number 3(2020) Page Start: e96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗